Concord Biotech Limited has submitted a regulatory filing pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
The disclosure is a follow-up to the company's intimation dated July 28, 2026, which was submitted to the Stock Exchanges regarding an Earnings Call in connection with the unaudited (Standalone and Consolidated) Financial Results for the first quarter ended June 30, 2026 (Q1 FY27).
The company informs that the Earnings Call was successfully conducted on August 03, 2026, at 3:30 P.M. (IST).
The audio recording of this conference call has been hosted on the company's website. The specific link provided for accessing the recording is: https://concordbiotech.com/wp-content/uploads/2026/08/Concord-Biotech-Q1-FY27-Earnings-Call-Audio-Recording.mp3.
The letter is signed by Paritosh Trivedi, Company Secretary and Compliance Officer (ACS 63623), on behalf of Concord Biotech Limited.